Activation of the Ras-mitogen-activated protein kinase (MAPK) pathway is also associated with a reduction of MHC, PD-L1, and TIL in TNBC, and consequently, MEK inhibitors in combination with anti-PD1 antibodies synergistically suppressed tumor growth in murine models [71]. The gene discussed is HLA-C; the disease is neoplasm.